Docusign Inc vs Edwards Lifesciences Corporation Common Stock — how do they compare? Docusign Inc trades at $72.2 (market cap $13.35B), while Edwards Lifesciences Corporation Common Stock trades at $85.18 (market cap $48.56B). The key difference: Edwards Lifesciences Corporation Common Stock is far larger — about 3.6× Docusign Inc's market cap, and Docusign Inc is trading nearer its 52-week high, Edwards Lifesciences Corporation Common Stock nearer its low. Which is the better fit depends on your goals.
| DOCU | EW | |
|---|---|---|
Market Cap | $13.35B | $48.56B |
Volume | 3,158,858 | 6,520,488 |
Sector | Technology | Health |
52-Week High | $73.14 | $95.18 |
52-Week Low | $41.75 | $72.65 |
Typical Hold Time | 71 Days | — |
Enterprise Value | $12.76B | $45.01B |
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $68.90, up 1.0% on the day, with a bullish technical signal from moving averages and consistent earnings beats in recent quarters. Revenue growth has accelerated to $2.98 billion in 2025, with net income surging to $1.07 billion. The company maintains strong profitability metrics, including a 79.49% gross margin and 17.8% ROE, while recent news highlights AI integration in contract processing and leadership in workflow software.
The outlook is supported by solid fundamentals and positive analyst sentiment, though valuation multiples like a P/E of 43.55 suggest premium pricing. Key risks include market saturation in e-signatures and insider selling activity. The consensus price target of $68.75 aligns closely with the current price, indicating a neutral near-term view with long-term growth potential from AI adoption.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →